NHS Saving £300M by Instructing Providers to Not Prescribe Branded Drugs Including Humira
NHS Has Cut Its Drug Spend by 29%
Humira Biosimilar IBI303 Does Well in Phase 3 Chinese Clinical Trial Led by Tsinghua University School of Medicine
Tsinghua University, School of Medicine and led a study comparing the efficacy and safety of IBI303 and the originator drug […]
TNF Inhibitors and Heart Failure—A Recent Concern for Hidradenitis Suppurativa Patients
The TrialSite Network includes many thousands of Hidradenitis Suppurativa patients eager for greater focus and investment, research, and breakthrough therapies for […]
Samsung Bioepis HUMIRA Biosimilar Approved in the U.S. & Will be Available in June 2023 Due to Patent Thicket
Samsung Bioepis Co. Ltd. reports that the U.S. FDA has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® (adalimumab) for the […]
First Patient Enrolled in Phase 3 Study Evaluating HUMIRA Biosmilar
Alvotech, whose drug candidate AVT02 is being developed as a biosimilar to adalimumab (Humira, AbbVie), enrolled the first patient in […]
Biosimilars Increase Prices!
A study from last year focusing on cost trends for tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis (RA) after […]
Hidradenitis Suppurativa Patient Website: Does It Live Up to Its Name?
Recently, a TrialSite News reader—a Hidradenitis Suppurativa (HS) patient—brought a website to our attention. Apparently, this individual, who has been […]
PharmaWatch: German Boehringer Ingelheim Taking on an American Thorny Thicket
Delaware federal court Judge Richard Lloret recently ordered AbbVie to immediately produce important Humira® documentation to defendant Boehringer Ingelheim (BI) […]
AbbVie Closed Another Humira Biosimilar Deal with Pfizer
See The Pharma Letter to learn more about a recent deal where AbbVie licensed biosimilar adalimumab to Pfizer. Under the […]
AbbVie and Abbott Labs Settle with Government to Resolve Claims & Kickback Allegations
Both Abbott Laboratories and AbbVie Inc. will settle with the federal government for allegations that they employed kickbacks and unlawful […]
